References
- Mand J, Morice R, Ouren C, Korten A. Use of antipsychotic medication in Australia between July 1995 and December 2001. Aust NZ Psychiatry 2003; 37: 55–61
- Waddington, JL, Kapur, S, Remington, GJ. The neuroscience and clinical psychopharmacology of first- and second-generation antipsychotic drugs. In: Hirsch SR, Weinberger, D, editors. Schizophrenia. 2nd ed. CambridgeMA: Blackwell Science; 2003.
- Citrome L, Volavka J. Optimal dosing of atypical antipsychotics in adults: A review of the current evidence. Harv Rev Psychiatry 2002; 10: 280–91
- Kane JM, Leucht S, Carpenter D, et al. Expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry 2003; 64(Suppl 12)5–19
- Keks N. Case vignettes. Re-integration of the schizophrenic patient, JA Lieberman. Science Press, London 1998
- American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry 1997;154(Suppl 4):1–63.
- Reinstein, MJ, Sonnenberg, JG, Chasanov, MA, , et al. NR353: Comparative efficacy and tolerability of quetiapine at high and low doses. Presented at the American Psychiatric Association, New Orleans, USA; 2001.
- Smith MA, McCoy R, Hamer-Maansson J, Brecher M. Rapid dose escalation with quetiapine: A pilot study. J Clin Psychopharmacol 2005; 25: 331–5
- Arango C, Bobes J. Managing acute exacerbations of schizophrenia: Focus on quetiapine. Curr Med Res Opin 2004; 5: 619–26